|
Apr 16
|
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics
|
|
Apr 11
|
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
|
|
Apr 2
|
Wall Street Analysts Predict a 407.94% Upside in Precision BioSciences (DTIL): Here's What You Should Know
|
|
Apr 2
|
Precision BioSciences (DTIL) Soars 13.4%: Is Further Upside Left in the Stock?
|
|
Mar 27
|
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 27
|
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
|
|
Mar 20
|
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024
|
|
Mar 19
|
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy
|
|
Mar 6
|
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
|
|
Jan 9
|
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
|
|
Jan 9
|
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
|
|
Dec 4
|
Precision BioSciences Announces Publication in Nature Metabolism Supporting ARCUS® In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases
|
|
Nov 30
|
Precision BioSciences to Present at Hep-DART 2023
|
|
Nov 28
|
Precision BioSciences Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 9
|
Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
|
|
Nov 7
|
Precision BioSciences Inc (DTIL) Reports Q3 2023 Financial Results
|
|
Nov 7
|
Precision BioSciences Reports Third Quarter 2023 Financial Results and Provides Business Update
|
|
Aug 6
|
Analysts Just Published A Bright New Outlook For Precision BioSciences, Inc.'s (NASDAQ:DTIL)
|
|
Aug 4
|
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 4
|
Precision BioSciences Reports Second Quarter 2023 Financial Results and Provides Business Update
|